Evidence map›Paper›PMID 26244281›Full record

ArticleExperimental neurology2015

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Ross B Mounsey, Sarah Mustafa, Lianne Robinson, Ruth A Ross, Gernot Riedel, Roger G Pertwee, Peter Teismann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Beyond dopamine: exploring endocannabinoids in Parkinson's disease.Ageing and neurodegenerative diseases · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Sapropterin (BH4) Aggravates Autoimmune Encephalomyelitis in Mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ross B MounseyInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK.
Sarah MustafaInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK.
Lianne RobinsonInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK; Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY Scotland, UK.
Ruth A RossDepartment of Pharmacology and Toxicology, University of Toronto, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario M5S 1A, Canada.
Gernot RiedelInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK.
Roger G PertweeInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK.
Peter TeismannInstitute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD Scotland, UK. Electronic address: p.teismann@abdn.ac.uk.

Funding

Wellcome Trust WT080782MF
6 · The paper itself

Abstract

Parkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin. Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are available but no treatment slows or prevents the loss of neurons. Neuroinflammation has been implicated in its pathogenesis. To this end, the present study utilises the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to reproduce the pattern of cell death evident in PD patients. Herein, the role of a potential regulator of an immune response, the endocannabinoid system (ECS), is investigated. The most prevalent endocannabinoid, 2-arachidonoylglycerol (2-AG) (3 and 5mg/kg), was added exogenously and its enzymatic degradation inhibited to provide protection against MPTP-induced cell death. Furthermore, the addition of DFU (25mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects. Levels of 2-AG were shown to be upregulated in a time- and region-specific manner following MPTP administration, indicating that the ECS represents a natural defence mechanism against inflammation, potentiation of which could provide therapeutic benefits. The results expand the current understanding of the role that this signalling system has and its potential influence in PD.

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsArachidonic AcidsBenzodioxolesBrainCell DeathCyclooxygenase 2Disease Models, AnimalDose-Response Relationship, DrugEndocannabinoidsEnzyme InhibitorsFuransGait Disorders, NeurologicGlyceridesMaleMice1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanoneArachidonic AcidsBenzodioxolesCyclooxygenase 2EndocannabinoidsEnzyme InhibitorsFuransGlyceridesglyceryl 2-arachidonateJZL 184Neuroprotective AgentsNeurotoxinsPiperidinesTyrosine 3-MonooxygenaseEndocannabinoidsMPTPNeuroprotectionParkinson's disease

Identifiers

PMID26244281
PMCPMC4654430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.